Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
Total Valuation
Tempest Therapeutics has a market cap or net worth of $27.32M. The enterprise value is $21.79M.
Market Cap$27.32M
Enterprise Value$21.79M
Share Statistics
Tempest Therapeutics has 3,520,321 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,520,321
Owned by Insiders8.16%
Owned by Institutions8.57%
Financial Efficiency
Tempest Therapeutics’s return on equity (ROE) is -2.19 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-2.19
Return on Assets (ROA)-1.01
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-1.74M
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tempest Therapeutics is -7.23. Tempest Therapeutics’s PEG ratio is 0.34.
PE Ratio-7.23
PS Ratio―
PB Ratio15.83
Price to Fair Value15.83
Price to FCF-9.05
Price to Operating Cash Flow-9.17
PEG Ratio0.34
Income Statement
In the last 12 months, Tempest Therapeutics had revenue of 0.00 and earned -41.84M in profits. Earnings per share was -1.50.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-41.84M
Net Income-41.84M
EBITDA0.00
Earnings Per Share (EPS)-1.50
Cash Flow
In the last 12 months, operating cash flow was -33.03M and capital expenditures -435.00K, giving a free cash flow of -33.46M billion.
Operating Cash Flow-33.03M
Free Cash Flow-33.46M
Free Cash Flow per Share-9.51
Dividends & Yields
Tempest Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.96
52-Week Price Change-82.65%
50-Day Moving Average9.66
200-Day Moving Average13.94
Relative Strength Index (RSI)44.51
Average Volume (3m)70.65K
Important Dates
Tempest Therapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Tempest Therapeutics as a current ratio of 2.21, with Debt / Equity ratio of 80.34%
Current Ratio2.21
Quick Ratio2.21
Debt to Market Cap0.05
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tempest Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tempest Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -8.60.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-8.60
EV to Operating Cash Flow-8.72
Balance Sheet
Tempest Therapeutics has $30.27M in cash and marketable securities with $15.37M in debt, giving a net cash position of -$14.90M billion.
Cash & Marketable Securities$30.27M
Total Debt$15.37M
Net Cash-$14.90M
Net Cash Per Share-$4.23
Tangible Book Value Per Share$0.69
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tempest Therapeutics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside-9.79% Downside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-220.54%